Skip to main content

Table 4 Sensitivity analysis of NK1RA co-administration for non-CR, non-CC, and non-TC during the overall study period

From: Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials

  PS-matched analysis PS-adjusted analysis IPTW
  OR 95% CI P value OR 95% CI P value OR 95% CI P value
A: non-CR
 NK1RA inclusive regimen (yes vs no) 2.10 0.36–12.11 0.406 1.50 0.36–6.31 0.579 2.25 0.59–8.58 0.233
B: non-CC
 NK1RA inclusive regimen (yes vs no) 2.69 0.49–14.69 0.253 1.95 0.48–7.89 0.348 2.74 0.70–10.67 0.146
C: non-TC
 NK1RA inclusive regimen (yes vs no) 1.41 0.44–4.46 0.561 1.77 0.61–5.11 0.293 2.68 1.07–6.72 0.036
  1. OR odds ratio; CI confidence interval; CR complete response; CC complete control; TC total control; PS propensity score; IPTW inverse probability of treatment weighting.